Wegovy HD vs Zepbound: Semaglutide’s New Dose Changes the GLP-1 Comparison

Your patients are asking: Should I take Wegovy or Zepbound? The answer used to be “either one works great.” But 2026 just got more complicated—and more interesting.

The Old Winner

For years, the data clearly favored tirzepatide (Zepbound). The SURMOUNT-5 trial showed tirzepatide at 72 weeks producing 21.6% body weight loss versus 15.4% for semaglutide. That 6-percentage-point gap was statistically significant and clinically meaningful.

Enter Wegovy HD

Novo Nordisk answered with Wegovy HD—a higher-dose formulation of semaglutide (7.2 mg, compared to the standard 2.4 mg maintenance dose). Head-to-head data now shows Wegovy HD performs at or slightly above Zepbound on weight loss outcomes.

The implication: patients already on semaglutide who plateaued on the standard dose may have a path forward that doesn’t require switching medications entirely.

The Mechanism

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual agonist—it hits both GLP-1 and GIP receptors. Wegovy HD works by pushing semaglutide dosing into a range where it can compete head-to-head with dual-receptor activation. It’s a semaglutide dose escalation story, not a new mechanism.

What hasn’t changed: tirzepatide still carries a higher rate of lean-body-mass loss in some patients. Wegovy HD, by remaining a single-receptor agonist at higher doses, may preserve more lean mass in muscular or older patients concerned about sarcopenia.

The Clinical Decision

• Start with Wegovy 2.4 mg if your patient is new to GLP-1 therapy, cost-sensitive, or has insurance that covers Wegovy preferentially.
• Consider Wegovy HD if your patient is already on semaglutide 2.4 mg and has plateaued—dose escalation before switching is a reasonable strategy.
• Consider Zepbound if maximum weight loss is the priority and insurance coverage makes it affordable, or if the patient has failed semaglutide at maximum dose.

What It Costs (April 2026)

• Zepbound (tirzepatide) — full dose: $449/month cash
• Wegovy (semaglutide 2.4 mg): $349/month cash
• Wegovy HD (semaglutide 7.2 mg): $399/month cash

With insurance coverage, these medications often cost as little as $25/month—depending on your plan. Clinical Nutrition Center offers prior authorization support for patients who have confirmed coverage. If you’ve checked with your carrier and have a policy that includes GLP-1 coverage, we’re happy to help navigate the paperwork.

Both medications significantly outperform older GLP-1 therapies. The question isn’t “which one is good?” It’s “which one is best for this patient—and can they afford it?”

Sources: AJMC Systematic Review (2026, 22 RCTs). SURMOUNT-5 Trial data via AJMC, Medical Dialogues, HCPLive. Wegovy HD (semaglutide 7.2 mg) — Novo Nordisk 2026 labeling update.